An Update on Therapeutic Angiogenesis for Peripheral Vascular Disease

Annals of Vascular Surgery

Volumn 24, Issue 2, 2010, Pages 258-268

  Pacilli, Annalisa ^a   Faggioli, Gianluca ^a   Stella, Andrea ^a   Pasquinelli, Gianandrea ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BASIC FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; SCATTER FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165;

ABSENCE OF SIDE EFFECTS; ANGIOGENESIS; ARTERY DISEASE; BONE MARROW TRANSPLANTATION; CELL THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ENDOTHELIUM CELL; GENE THERAPY; GENE TRANSFER; HUMAN; INJECTION SITE EDEMA; INTERMITTENT CLAUDICATION; LEG ISCHEMIA; LIMB ISCHEMIA; OXYGEN TENSION; PAIN; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING;

ANGIOGENIC PROTEINS; ANIMALS; ENDOTHELIAL CELLS; GENE THERAPY; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL VASCULAR DISEASES; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TREATMENT OUTCOME;

EID: 75149168345     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.avsg.2008.12.003     Document Type: Review

References (57)

1. Sata M., Saiura A., Kunisato A., et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 8 (2002) 403-409
2. Shimizu K., Sugiyama S., Aikawa M., et al. Host bone-marrow cells are a source of donor intimal smooth muscle-like cells in murine aortic transplant arteriopathy. Nat Med 7 (2001) 738-741
3. Hillebrands J.-L., Klatter F.A., and Vandenhurk B.M.H. Origin of neointimal endothelium and α-actin-positive smooth muscle cells in transplant arteriosclerosis. J Clin Invest 107 (2001) 1411-1422
4. Werner N., Priller J., Laufs U., et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol. 22 (2002) 1567-1572
5. Xu Q., Zhang Z., Davison F., et al. Circulating progenitor cells regenerate endothelium of vein graft atherosclerosis, which is diminished in apoE-deficient mice. Circ Res. 93 (2003) e76-e86
6. Griese D.P., Ehsan A., Melo L.G., et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation 108 (2003) 2710-2715
7. Werner N., Junk S., Laufs U., et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res (2003) 93 e17-e24
8. Wassmann S., Werner N., Czech T., et al. Improvement of endothelial function by systemic transfusion of vascular progenitor cells. Circ Res. 99 (2006) e74-e83
9. Kong D., Melo L.G., Gnecchi M., et al. Cytokine-induced mobilization of circulating endothelial progenitor cells, enhances repair of injured arteries. Circulation 110 (2004) 2039-2046
10. Yoshioka T., Takahashi M., Shiba Y., et al. Granulocyte-colony stimulating factor (G-CSF) accelerates reendothelialization and reduces neointimal formation after vascular injury in mice. Cardiovasc Res. 70 (2006) 61-69
11. Vasa M., Fichtlscherer S., Adler K., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103 (2001) 2885-2890
12. Orlic D., Kajstura J., Chimenti S., et al. Transplanted adult bone marrow cells repair myocardial infarcts in mice. Ann. N.Y Acad Sci 938 (2001) 221-229
13. Iba O., Matsubara H., Nozawa Y., et al. Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischaemic limbs. Circulation 106 (2002) 2019-2025
14. Kalka C., Masuda H., Takahashi T., et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 97 (2000) 3422-3427
15. Boyle A.J., Schulman S.P., Hare J.M., et al. Is stem cell therapy ready for patients? Stem cell therapy for cardiac repair: ready for the next step. Circulation 114 (2006) 339-352
16. Oettgen P., Boyle A.J., Schulman S.P., et al. Cardiac stem cell therapy. Need for optimization of efficacy and safety monitoring. Circulation 114 (2006) 353-358
17. Lazarous D.F., Unger E.F., Epstein S.E., et al. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol 36 (2000) 1239-1244
18. Rajagopalan S., Trachtenberg J., Mohler E., et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Am. J Cardiol 90 (2002) 512-516
19. Isner J.M., Pieczek A., Schainfeld R., et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348 (1996) 370-374
20. Baumgartner I., Pieczek A., Manor O., et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97 (1998) 1114-1123
21. Shyu K.G., Chang H., Wang B.W., et al. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am. J Med 114 (2003) 85-92
22. Comerota A.J., Throm R.C., Miller K.A., et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 35 (2002) 930-936
23. Lederman R.J., Mendelsohn F.O., Anderson R.D., et al., TRAFFIC Investigators. Therapeutic Angiogenesis with Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication (the TRAFFIC study): a randomised trial. Lancet 359 (2002) 2053-2058
24. Rajagopalan S., Mohler III E.R., Lederman R.J., et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108 (2003) 1933-1938
25. Mäkinen K., Manninen H., Hedman M., et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 6 (2002) 127-133
26. Powell R.J., Simons M., Mendelsohn F.O., et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 118 (2008) 58-65
27. Nikol S., Baumgartner I., Van Belle E., et al., TALISMAN 201 investigators. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 16 (2008) 972-978
28. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
29. Tateishi-Yuyama E., Matsubara H., Murohara T., et al. Therapeutic Angiogenesis using Cell Transplantation (TACT) study investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 360 (2002) 427-435
30. Higashi Y., Kimura M., Hara K., et al. Autologous bone-marrow mononuclear cell implantation improves endothelium-dependent vasodilation in patients with limb ischemia. Circulation 109 (2004) 1215-1218
31. Miyamoto M., Yasutake M., Takano H., et al. Therapeutic angiogenesis by autologous bone marrow cell implantation for refractory chronic peripheral arterial disease using assessment of neovascularization by 99mTc-tetrofosmin (TF) perfusion scintigraphy. Cell Transplant 13 (2004) 429-437
32. Nizankowski R., Petriczek T., Skotnicki A., et al. The treatment of advanced chronic lower limb ischaemia with marrow stem cell autotransplantation. Kardiol Pol 63 (2005) 351-360
33. Bartsch T., Brehm M., Zeus T., et al. Transplantation of autologous mononuclear bone marrow stem cells in patients with peripheral arterial disease (the TAM-PAD study). Clin Res Cardiol 96 (2007) 891-899
34. Van Tongeren R.B., Hamming J.F., Fibbe W.E., et al. Intramuscular or combined intramuscular/intra-arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. J Cardiovasc Surg (Torino) 49 (2008) 51-58
35. Esato K., Hamano K., Li T.S., et al. Neovascularization induced by autologous bone marrow cell implantation in peripheral arterial disease. Cell Transplant 11 (2002) 747-752
36. Saigawa T., Kato K., Ozawa T., et al. Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells. Circ J 68 (2004) 1189-1193
37. Kajiguchi M., Kondo T., Izawa H., et al. Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ J 71 (2007) 196-201
38. Durdu S., Akar A.R., Arat M., et al. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. J Vasc Surg 44 (2006) 732-739
39. Miyamoto K., Nishigami K., Nagaya N., et al. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation 114 (2006) 2679-2684
40. Kirana S., Stratmann B., Lammers D., et al. Wound therapy with autologous bone marrow stem cells in diabetic patients with ischaemia-induced tissue ulcers affecting the lower limbs. Int J Clin Pract 61 (2007) 690-692
41. Van Huyen J.P., Smadja D.M., Bruneval P., et al. Bone marrow-derived mononuclear cell therapy induces distal angiogenesis after local injection in critical leg ischemia. Mod Pathol 21 (2008) 837-846
42. Lenk K., Adams V., Lurz P., et al. Therapeutical potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia. Eur Heart J 26 (2005) 1903-1909
43. Huang P.P., Li S.Z., Han M.Z., et al. Autologous transplantation of peripheral blood stem cells as an effective therapeutic approach for severe arteriosclerosis obliterans of lower extremities. Thromb Haemost 91 (2004) 606-609
44. Kawamura A., Horie T., Tsuda I., et al. Prevention of limb amputation in patients with limbs ulcers by autologous peripheral blood mononuclear cell implantation. Ther Apher Dial 9 (2005) 59-63
45. Kawamura A., Horie T., Tsuda I., et al. Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs. J Artif Organs 9 (2006) 226-233
46. Huang P., Li S., Han M., et al. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 28 (2005) 2155-2160
47. Ishida A., Ohya Y., Sakuda H., et al. Autologous peripheral blood mononuclear cell implantation for patients with peripheral arterial disease improves limb ischemia. Circ J 69 (2005) 1260-1265
48. Kolvenbach R., Kreissig C., Ludwig E., et al. Stem cell use in critical limb ischemia. J Cardiovasc Surg (Torino) 48 (2007) 39-44
49. +) for therapeutic angiogenesis in patients with critical limb ischemia. Int Angiol 22 (2003) 344-348
50. +) for therapeutic vasculogenesis in a patient with critical limb ischemia. One year follow-up. Cytotherapy 9 (2007) 99-102
51. Huang P.P., Yang X.F., Li S.Z., et al. Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost 98 (2007) 1335-1342
52. Nanomedicine, Nanotechnology for Health. European Technology Platform, Strategic Research Agenda for Nanomedicine. September 2006.
53. Campbell G.R., and Campbell J.H. Development of tissue engineered vascular grafts. Curr Pharm Biotechnol 8 (2007) 43-50
54. Hoening M.R., Campbell G.R., Rolfe B.E., et al. Tissue-engineered blood vessels: alternative to autologous grafts?. Arterioscler Thromb Vasc Biol. 25 (2005) 1128-1134
55. Hobo K., Shimizu T., Sekine H., et al. Therapeutic angiogenesis using tissue engineered human smooth muscle cell sheets. Arterioscler Thromb Vasc Biol. 28 (2008) 637-643
56. L'Heureux N., Paquet S., Labbe R., et al. A completely biological tissue-engineered human blood vessel. FASEB J 12 (1998) 47-56
57. L'Heureux N., Dusserre N., Marini A., et al. Technology insight: the evolution of tissue-engineered vascular grafts-from research to clinical practice. Nat Clin Pract Cardiovasc Med 4 (2007) 389-395